PNPLA3 status and tirzepatide liver fat
Background research from the SURPASS-3 MRI substudy suggests that PNPLA3 I148M status did not materially differentiate the reported tirzepatide-associated liver-fat and cardiometabolic changes in this studied population, but the evidence is exploratory and cannot quantify genotype-specific effects from the supplied material.
Evidence
This report contains only one supplied briefing: background research, not a current-news confirmation. It summarizes a post hoc analysis of the phase 3, open-label SURPASS-3 MRI substudy. Insulin-naive adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor, were randomized 1:1:1:1 to weekly tirzepatide 5, 10, or 15 mg or daily insulin degludec. PNPLA3 I148M status was determined from blood DNA using a TaqMan allelic-discrimination assay; CC denoted absence of the allele, while CG and GG denoted its presence.
Among tirzepatide-treated participants, changes from baseline to Week 52 included significant reductions in MRI-assessed liver fat content, body weight, waist circumference, HbA1c, and fasting serum glucose (each reported as p < 0.001). The supplied material does not report the substudy sample size, genotype-specific effect sizes, confidence intervals, or absolute changes.
No statistically significant differences in reported outcomes were found between PNPLA3 genotype subgroups. Treatment-by-genotype interactions at Week 52 were not significant except for ALT and liver fat content (p < 0.05); the briefing attributes those interactions to differences between GG and CG participants in the insulin degludec arm, rather than to a demonstrated genotype-specific tirzepatide effect.
Analysis
The central signal is consistency, not precision medicine. Within this exploratory analysis, the direction of tirzepatide-associated improvement in liver fat and several metabolic measurements was similar whether or not participants carried PNPLA3 I148M. That supports the limited conclusion that the allele did not appear to alter the reported response pattern in this specific study population.
Because no genotype-specific magnitudes or precision estimates are supplied, the evidence cannot establish equivalence across genotypes or quantify any possible difference in treatment response. Statistical significance in the listed within-treatment changes also does not by itself establish clinical significance.
Limitations
This was a post hoc, exploratory analysis with a small sample size. Analyses were not adjusted for baseline body weight or ethnicity, creating potential confounding. The non-White population was small, and Hispanic or Latino representation was imbalanced across genotype subgroups, limiting generalizability. These findings should therefore be interpreted as population-specific background research rather than independent confirmation of a genotype-neutral tirzepatide effect.